Ziopharm Oncology Inc., of Boston, said it entered into an agreement with existing investors for the exercise of previously issued warrants to purchase common stock in a private placement, being led by existing stockholder, MSD Partners LP, that is expected to result in gross proceeds of approximately $45 million. Concurrently, in the private placement, Ziopharm will issue new warrants to purchase up to 15 million additional shares of common stock with an exercise price of $7. The funds help strengthen the company's balance sheet and will fund operations into 2021.

No Comments